Qingmin Chen

Qingmin Chen is an accomplished professional in the field of pharmacology with extensive experience in biopharmaceutical research and development. Currently serving as Vice President and Head of in vivo Pharmacology at Atalanta Therapeutics since January 2020, Qingmin has previously held senior leadership roles as Senior Director at Renascent Biosciences from 2019 to January 2020 and at Voyager Therapeutics, Inc. from 2015 to 2019. Earlier career positions include Principal Scientist and Senior Scientist II at Voyager Therapeutics and Sr. Scientist at Synageva BioPharma Corp. and Alnylam Pharmaceuticals. Qingmin Chen's academic background includes a Ph.D. and MS in Medical Pharmacology and Pharmacology and Toxicology from the University of Arizona College of Medicine – Tucson, as well as an MD from Shandong University. Prior experience includes an academic position as Assistant Professor in the Human Anatomy Department at Shandong Medical University from 1996 to 2001.